缺血性脑卒中TIA 二级预防抗血小板药物规范化应用的中国专家共识精品文档课件.pptVIP

下载本文档

1
0
约2.47万字
约 43页
2018-06-12 发布于贵州
举报
版权申诉

缺血性脑卒中TIA 二级预防抗血小板药物规范化应用的中国专家共识精品文档课件.ppt

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

缺血性脑卒中TIA 二级预防抗血小板药物规范化应用的中国专家共识精品文档课件

* In CAPRIE, 3,837 patients had co-existing diabetes.1 These patients are at higher risk of myocardial infarction, ischemic stroke, vascular death or hospitalization for ischemic events/bleeding (17.7% diabetic vs 12.7% non-diabetic in the ASA group; 15.6% diabetic vs 11.8% non-diabetic in the clopidogrel group).2,3 The annual event rate per 1,000 patients was reduced in the clopidogrel group vs the ASA group: by 38 in patients receiving insulin at baseline, 21 in diabetic patients who were not receiving insulin, compared with 11 in the overall CAPRIE population. The benefits of clopidogrel over ASA were amplified in the higher risk, insulin-dependent patients. References: 1. CAPRIE Steering Committee. Lancet 1996; 348: 1329–39. 2. Jarvis B, Simpson K. Drugs 2000; 60: 347–77. 3. Bhatt DL et al. Am Heart J 2000; 140: 67–73. * In CAPRIE,1 8,854 patients had a prior history of any ischemic event, and of these 4,496 had a history of a major acute event – a myocardial infarction or a stroke.1 The annual event rate per 1,000 patients was reduced in the clopidogrel group vs the ASA group by 34 in patients with a prior history of a major acute event, and by 28 in those with a prior history of any ischemic event, compared with 11 in the overall population.1,2 The benefits of clopidogrel over ASA were amplified in the higher vascular risk group.3 References: 1. CAPRIE Steering Committee. Lancet 1996; 348: 1329–39. 2. Jarvis B, Simpson K. Drugs 2000; 60: 34–77. 3. Ringleb PA. Eur Heart J 1999; 20: 666. * * 23.01.08 PAR * 23.01.08 PAR * * Pathogenesis of ICAS related infarction is different from SAD, and CE Unstable plaque (often with mixed mechanisms) A-A embolism Penetrating A occlusion Hypo-flow Usually + microemboli * Pathogenesis of ICAS related infarction is different from SAD, and CE Unstable plaque A-A embolism Penetrating A occlusion Hypo-flow, usually + microemboli * Pathogenesis of ICAS related infarction is different from SAD, and CE Unstable plaque A